Alcami Promotes Veteran Guy Kubi for COO to Helm Aggressive Expansion

DURHAM, N.C. – January 28, 2026 – Alcami Corporation, a leading U.S.-based contract development and manufacturing organization (CDMO), announced today the promotion of Guy Kubi to Chief Operating Officer. The appointment, effective immediately, is a significant strategic move to consolidate leadership as the company navigates what Kubi himself describes as a "monumental period of growth."

In his newly expanded role, Kubi will report directly to Chairman and CEO Patrick Walsh and assume oversight of a wide array of critical functions, including Human Resources, Quality, Commercial operations, Project Management, Corporate Development, and the company's Pharma Storage and Services Operations. The move centralizes key operational and commercial responsibilities under a single, long-tenured executive, signaling a clear intent to streamline decision-making and enhance operational cohesion during a phase of rapid scaling.

"Guy has been instrumental in cultivating high‑growth and client-centric culture while delivering business success," said Patrick Walsh in a statement. "His proven tenacity and leadership will serve Alcami well in the next phase of growth and expansion."

A Strategic Consolidation for Market Dominance

Kubi's promotion from his previous role as Chief Business Officer is more than a simple change in title; it represents a fundamental restructuring designed to support Alcami's ambitious growth trajectory. By bringing disparate departments under one operational umbrella, the company appears poised to improve efficiency and responsiveness, critical attributes in the competitive CDMO landscape.

This consolidation comes as Alcami reports significant financial momentum, with Kubi noting the company achieved "double digit growth to both top and bottom lines" in 2025. He anticipates this will "further accelerate in 2026 as Alcami continues to be a strong and preferred partner in the industry." Integrating commercial strategy with project management, quality control, and HR under a single COO ensures that business development and operational execution are tightly aligned, allowing the organization to capitalize on market opportunities more effectively.

Riding the Wave of CDMO Expansion

Alcami's aggressive growth strategy is unfolding against the backdrop of a booming U.S. CDMO market. The pharmaceutical industry's increasing reliance on outsourcing to cut costs, access specialized expertise, and accelerate drug development has created immense demand. Alcami has strategically positioned itself to capture a significant share of this market, particularly in high-growth segments.

The company has made substantial capital investments, pouring over $140 million between 2020 and 2022 into adding five state-of-the-art sterile fill-finish manufacturing lines and expanding its laboratory space. This focus on sterile fill-finish capabilities for both biologics and small molecules directly addresses the explosive growth in the biologics sector. Furthermore, a series of strategic acquisitions have broadened Alcami's service offerings and geographic footprint. Key acquisitions include TriPharm Services in 2020 (a sterile fill-finish manufacturer), Masy BioServices in 2021 (a cGMP biostorage specialist), and Pacific Pharmaceutical Services in early 2024 (a cGMP pharma storage provider). These moves have created an integrated, end-to-end service portfolio that is highly attractive to pharmaceutical and biotech clients seeking resilient and comprehensive supply chain partners.

The Influence of Private Equity Powerhouses

Fueling Alcami's rapid expansion is the formidable backing of its private equity owners: GHO Capital, The Vistria Group, and Ampersand Capital Partners. GHO Capital and The Vistria Group acquired a controlling interest in the company in early 2023, bringing a clear mandate for growth and market leadership. GHO Capital, a specialist healthcare investment advisor, is known for building market-leading businesses and has expressed intentions to help Alcami expand its partnerships into Europe.

This private equity ownership provides not only the capital for acquisitions and facility expansions but also a strategic imperative for operational excellence and efficiency. The promotion of an internal leader like Kubi, with a deep understanding of the company's financial and operational levers, aligns perfectly with a private equity playbook focused on maximizing value through streamlined, high-growth operations. The consolidation of functions under the new COO role can be seen as a direct reflection of this influence, aimed at creating a more agile and scalable corporate structure.

A Non-Traditional Path to the C-Suite

Kubi's journey to the COO office is a testament to the value of cross-functional expertise. He began his career at Alcami in the Finance department after earning a finance degree as a Division I tennis scholar-athlete from Winthrop University. With a CPA license (inactive) in North Carolina, his initial foundation was in financial management and analysis.

His career path included a stint at Avista Pharma Solutions, where he served as Controller and managed key financial and capital initiatives through a period of significant expansion that led to its acquisition. Upon returning to Alcami, he took on roles of increasing responsibility, including Site Controller for a critical sterile fill-finish site and, most recently, Chief Business Officer. This trajectory—from finance to site operations to enterprise-wide business strategy—has equipped Kubi with a unique, holistic perspective on the company. His deep financial acumen combined with hands-on experience in commercial growth and operational integration makes him uniquely suited to oversee Alcami's complex, science-driven operations while keeping a sharp eye on the bottom line.

Evolving Leadership for a New Growth Phase

Kubi's appointment is the latest in a series of leadership changes that indicate Alcami is actively reshaping its executive team to manage its next chapter. Patrick Walsh has been at the helm as Chairman and CEO since January 2025, suggesting a relatively new top-level strategy is being implemented. The same day as Kubi's promotion, it was announced that Jacquelyn Martin, Alcami's former Chief Quality and Regulatory Compliance Officer, was transitioning to a new role at another company, marking a notable change in the quality leadership.

These moves, combined with key leadership appointments within the Drug Product Manufacturing division in mid-2025, paint a picture of a company in dynamic transition. The organization is strategically placing and promoting leaders with proven track records in scaling operations and driving growth. This series of strategic appointments and consolidations positions Alcami with a reshaped executive team purpose-built to navigate the next phase of its ambitious growth plan.